Share Price and Basic Stock Data
Last Updated: December 11, 2024, 11:18 pm
PEG Ratio | -9.19 |
---|
Competitors of Arvee Laboratories (India) Ltd
Stock Name | Market Cap | Current Price | High / Low | Stock P/E | Book Value | Dividend Yield | ROCE | ROE | Face Value |
---|---|---|---|---|---|---|---|---|---|
HP Adhesives Ltd | 758 Cr. | 82.7 | 131/75.0 | 36.8 | 19.2 | 0.36 % | 17.7 % | 12.6 % | 2.00 |
Haryana Leather Chemicals Ltd | 44.9 Cr. | 91.5 | 124/56.8 | 9.94 | 87.2 | 1.09 % | 8.96 % | 7.25 % | 10.0 |
Hardcastle & Waud Mfg Co Ltd | 65.6 Cr. | 964 | 1,355/448 | 34.3 | 663 | 0.00 % | 7.00 % | 5.98 % | 10.0 |
Grauer & Weil (India) Ltd | 4,729 Cr. | 104 | 120/60.1 | 29.5 | 19.2 | 0.48 % | 26.1 % | 19.6 % | 1.00 |
DMCC Speciality Chemicals Ltd | 925 Cr. | 372 | 403/245 | 69.8 | 85.4 | 0.27 % | 10.8 % | 5.68 % | 10.0 |
Industry Average | 13,579.85 Cr | 968.04 | 60.36 | 173.84 | 0.30% | 14.09% | 10.82% | 6.44 |
Quarterly Result
Month | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 9.06 | 10.70 | 7.90 | 12.67 | 18.18 | 22.74 | 16.25 | 12.56 | 7.60 | 8.91 | 7.70 | 6.14 | 10.60 |
Expenses | 7.63 | 9.00 | 6.89 | 11.13 | 15.92 | 19.48 | 14.51 | 11.40 | 6.62 | 8.22 | 7.17 | 5.35 | 9.06 |
Operating Profit | 1.43 | 1.70 | 1.01 | 1.54 | 2.26 | 3.26 | 1.74 | 1.16 | 0.98 | 0.69 | 0.53 | 0.79 | 1.54 |
OPM % | 15.78% | 15.89% | 12.78% | 12.15% | 12.43% | 14.34% | 10.71% | 9.24% | 12.89% | 7.74% | 6.88% | 12.87% | 14.53% |
Other Income | 0.06 | 0.07 | 0.12 | 0.21 | 0.02 | 0.06 | 0.07 | 0.06 | 0.09 | 0.09 | 0.19 | 0.21 | 0.11 |
Interest | 0.12 | 0.06 | 0.09 | 0.09 | 0.11 | 0.11 | 0.09 | 0.07 | 0.07 | 0.08 | 0.05 | 0.05 | 0.08 |
Depreciation | 0.66 | 0.67 | 0.38 | 0.62 | 0.64 | 0.48 | 0.49 | 0.48 | 0.35 | 0.42 | 0.35 | 0.37 | 0.31 |
Profit before tax | 0.71 | 1.04 | 0.66 | 1.04 | 1.53 | 2.73 | 1.23 | 0.67 | 0.65 | 0.28 | 0.32 | 0.58 | 1.26 |
Tax % | 25.35% | 29.81% | -74.24% | 24.04% | 24.84% | 25.27% | 25.20% | 100.00% | 24.62% | 25.00% | 25.00% | 81.03% | 25.40% |
Net Profit | 0.53 | 0.73 | 1.16 | 0.79 | 1.14 | 2.05 | 0.92 | 0.01 | 0.49 | 0.21 | 0.24 | 0.12 | 0.94 |
EPS in Rs | 0.48 | 0.66 | 1.05 | 0.72 | 1.03 | 1.86 | 0.83 | 0.01 | 0.44 | 0.19 | 0.22 | 0.11 | 0.85 |
Last Updated: September 11, 2024, 3:08 pm
Profit & Loss - Annual Report
Last Updated: September 11, 2024, 3:08 pm
Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Sales | 26.82 | 34.44 | 47.78 | 54.90 | 45.42 | 47.38 | 40.33 | 61.35 | 30.35 | 33.35 |
Expenses | 21.83 | 28.54 | 40.61 | 48.73 | 39.40 | 41.31 | 34.65 | 54.06 | 27.35 | 29.80 |
Operating Profit | 4.99 | 5.90 | 7.17 | 6.17 | 6.02 | 6.07 | 5.68 | 7.29 | 3.00 | 3.55 |
OPM % | 18.61% | 17.13% | 15.01% | 11.24% | 13.25% | 12.81% | 14.08% | 11.88% | 9.88% | 10.64% |
Other Income | 0.10 | 0.51 | 0.23 | 0.35 | 0.35 | 0.56 | 0.46 | 1.35 | 0.58 | 0.60 |
Interest | 3.07 | 3.48 | 3.33 | 1.63 | 0.99 | 0.58 | 0.37 | 0.39 | 0.25 | 0.26 |
Depreciation | 1.49 | 2.07 | 2.15 | 2.35 | 2.29 | 2.41 | 2.32 | 2.08 | 1.50 | 1.45 |
Profit before tax | 0.53 | 0.86 | 1.92 | 2.54 | 3.09 | 3.64 | 3.45 | 6.17 | 1.83 | 2.44 |
Tax % | 66.04% | -81.40% | 43.23% | 11.02% | 25.89% | 26.37% | 25.51% | 33.23% | 42.62% | |
Net Profit | 0.19 | 1.55 | 1.09 | 2.26 | 2.30 | 2.68 | 2.57 | 4.12 | 1.05 | 1.51 |
EPS in Rs | 0.23 | 1.91 | 0.99 | 2.05 | 2.09 | 2.43 | 2.33 | 3.74 | 0.95 | 1.37 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | 715.79% | -29.68% | 107.34% | 1.77% | 16.52% | -4.10% | 60.31% | -74.51% |
Change in YoY Net Profit Growth (%) | 0.00% | -745.47% | 137.02% | -105.57% | 14.75% | -20.63% | 64.42% | -134.83% |
Arvee Laboratories (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2023-2024.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -11% |
3 Years: | -14% |
TTM: | -18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -14% |
3 Years: | -26% |
TTM: | 40% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 50% |
3 Years: | 33% |
1 Year: | 9% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 11% |
3 Years: | 10% |
Last Year: | 4% |
Last Updated: Unknown
Balance Sheet
Last Updated: November 15, 2024, 1:41 am
Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4.05 | 4.05 | 5.51 | 5.51 | 5.51 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 |
Reserves | -1.41 | 0.15 | 8.69 | 10.95 | 13.25 | 10.42 | 12.92 | 17.04 | 18.09 | 20.02 |
Borrowings | 25.32 | 24.99 | 16.15 | 12.87 | 3.87 | 8.88 | 3.13 | 1.00 | 1.00 | 1.00 |
Other Liabilities | 7.25 | 6.49 | 13.77 | 7.81 | 11.00 | 10.73 | 11.61 | 9.63 | 8.08 | 8.01 |
Total Liabilities | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 40.05 |
Fixed Assets | 13.15 | 16.88 | 14.88 | 12.65 | 13.18 | 13.81 | 13.84 | 12.68 | 12.67 | 12.98 |
CWIP | 4.30 | 0.00 | 1.18 | 2.32 | 1.78 | 0.97 | 0.98 | 1.53 | 2.62 | 2.75 |
Investments | 0.00 | 0.00 | 0.00 | 1.95 | 3.09 | 2.03 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Assets | 17.76 | 18.80 | 28.06 | 20.22 | 15.58 | 24.24 | 23.86 | 24.48 | 22.90 | 24.32 |
Total Assets | 35.21 | 35.68 | 44.12 | 37.14 | 33.63 | 41.05 | 38.68 | 38.69 | 38.19 | 40.05 |
Cash Flow
Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | -20.33 | -19.09 | -8.98 | -6.70 | 2.15 | -2.81 | 2.55 | 6.29 | 2.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 82.61 | 87.12 | 118.25 | 52.66 | 52.40 | 60.70 | 109.78 | 72.94 | 73.48 |
Inventory Days | 155.08 | 104.53 | 99.61 | 42.90 | 80.96 | 91.96 | 93.24 | 42.29 | 159.02 |
Days Payable | 130.73 | 98.14 | 150.03 | 55.84 | 125.63 | 118.08 | 160.12 | 73.30 | 164.49 |
Cash Conversion Cycle | 106.96 | 93.50 | 67.84 | 39.72 | 7.72 | 34.59 | 42.90 | 41.94 | 68.01 |
Working Capital Days | 115.54 | 107.57 | 82.73 | 44.88 | 25.64 | 50.07 | 69.24 | 70.44 | 95.97 |
ROCE % | 15.19% | 17.64% | 13.67% | 14.90% | 14.92% | 12.89% | 23.34% | 6.83% |
This stock is not held by any mutual fund
Key Financial Ratios
Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
---|---|---|---|---|---|
FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Basic EPS (Rs.) | 0.95 | 3.74 | 2.34 | 2.43 | 4.04 |
Diluted EPS (Rs.) | 0.95 | 3.74 | 2.34 | 2.43 | 4.04 |
Cash EPS (Rs.) | 2.31 | 5.63 | 4.44 | 4.61 | 8.20 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 26.42 | 25.46 | 21.73 | 19.45 | 33.92 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 26.42 | 25.46 | 21.73 | 19.45 | 33.92 |
Revenue From Operations / Share (Rs.) | 27.54 | 55.67 | 36.59 | 42.99 | 82.43 |
PBDIT / Share (Rs.) | 3.25 | 7.83 | 5.56 | 6.01 | 11.56 |
PBIT / Share (Rs.) | 1.89 | 5.95 | 3.46 | 3.83 | 7.40 |
PBT / Share (Rs.) | 1.66 | 5.59 | 3.13 | 3.30 | 5.61 |
Net Profit / Share (Rs.) | 0.95 | 3.74 | 2.34 | 2.43 | 4.04 |
PBDIT Margin (%) | 11.78 | 14.07 | 15.19 | 13.98 | 14.01 |
PBIT Margin (%) | 6.85 | 10.68 | 9.44 | 8.90 | 8.97 |
PBT Margin (%) | 6.02 | 10.04 | 8.55 | 7.68 | 6.80 |
Net Profit Margin (%) | 3.46 | 6.71 | 6.38 | 5.65 | 4.90 |
Return on Networth / Equity (%) | 3.61 | 14.67 | 10.75 | 12.48 | 11.91 |
Return on Capital Employeed (%) | 6.65 | 21.95 | 15.14 | 18.53 | 19.35 |
Return On Assets (%) | 2.72 | 10.64 | 6.65 | 6.52 | 6.62 |
Long Term Debt / Equity (X) | 0.03 | 0.03 | 0.04 | 0.04 | 0.10 |
Total Debt / Equity (X) | 0.03 | 0.03 | 0.13 | 0.41 | 0.11 |
Asset Turnover Ratio (%) | 0.78 | 1.59 | 1.01 | 1.27 | 1.28 |
Current Ratio (X) | 3.11 | 2.44 | 1.75 | 1.40 | 1.44 |
Quick Ratio (X) | 2.23 | 1.92 | 1.33 | 0.99 | 0.92 |
Inventory Turnover Ratio (X) | 3.10 | 7.48 | 3.53 | 4.18 | 5.46 |
Interest Coverage Ratio (X) | 14.32 | 22.25 | 17.08 | 11.49 | 6.45 |
Interest Coverage Ratio (Post Tax) (X) | 5.21 | 11.62 | 8.17 | 5.64 | 3.25 |
Enterprise Value (Cr.) | 151.49 | 97.08 | 123.80 | 63.32 | 27.09 |
EV / Net Operating Revenue (X) | 4.99 | 1.58 | 3.07 | 1.34 | 0.59 |
EV / EBITDA (X) | 42.34 | 11.25 | 20.20 | 9.56 | 4.25 |
MarketCap / Net Operating Revenue (X) | 5.21 | 1.58 | 3.11 | 1.29 | 0.57 |
Price / BV (X) | 5.43 | 3.46 | 5.23 | 2.85 | 1.39 |
Price / Net Operating Revenue (X) | 5.21 | 1.58 | 3.11 | 1.29 | 0.57 |
EarningsYield | 0.01 | 0.04 | 0.02 | 0.04 | 0.08 |
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Arvee Laboratories (India) Ltd:
- Net Profit Margin: 3.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.65% (Industry Average ROCE: 14.09%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.61% (Industry Average ROE: 10.48%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.23
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 99.5 (Industry average Stock P/E: 50.93)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.46%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Chemicals - Speciality - Others | 403, Entice, Nr. Jayantilal Park BRTS, Ahmedabad Gujarat 380058 | compliance@arveelabs.com http://www.arveelabs.com |
Management | |
---|---|
Name | Position Held |
Mr. Shalin Sudhakarbhai Patel | Managing Director |
Mr. Shalin Bharat Chokshi | Whole Time Director |
Mrs. Neetu Rishi Jalan | Independent Director |
Mr. Dipen Ashit Dalal | Independent Director |
Mr. Sachin Kanwarlal Kansal | Independent Director |
Ms. Shalini Hitesh Jalan | Independent Director |
FAQ
What is the latest intrinsic value of Arvee Laboratories (India) Ltd?
The latest intrinsic value of Arvee Laboratories (India) Ltd as on 12 December 2024 is ₹101.03, which is 50.96% lower than the current market price of ₹206.00. The stock has a market capitalization of 227 Cr. and recorded a high/low of ₹315/117 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹20.02 Cr and total liabilities of ₹40.05 Cr.
What is the Market Cap of Arvee Laboratories (India) Ltd?
The Market Cap of Arvee Laboratories (India) Ltd is 227 Cr..
What is the current Stock Price of Arvee Laboratories (India) Ltd as on 12 December 2024?
The current stock price of Arvee Laboratories (India) Ltd as on 12 December 2024 is 206.
What is the High / Low of Arvee Laboratories (India) Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of Arvee Laboratories (India) Ltd stocks is 315/117.
What is the Stock P/E of Arvee Laboratories (India) Ltd?
The Stock P/E of Arvee Laboratories (India) Ltd is 99.5.
What is the Book Value of Arvee Laboratories (India) Ltd?
The Book Value of Arvee Laboratories (India) Ltd is 28.2.
What is the Dividend Yield of Arvee Laboratories (India) Ltd?
The Dividend Yield of Arvee Laboratories (India) Ltd is 0.00 %.
What is the ROCE of Arvee Laboratories (India) Ltd?
The ROCE of Arvee Laboratories (India) Ltd is 6.83 %.
What is the ROE of Arvee Laboratories (India) Ltd?
The ROE of Arvee Laboratories (India) Ltd is 3.53 %.
What is the Face Value of Arvee Laboratories (India) Ltd?
The Face Value of Arvee Laboratories (India) Ltd is 10.0.